Dashner Adam, Siders PharmD Erin
Encompass Health Rehabilitation Hospital of Harmarville, Pittsburgh, PA, USA.
J Pharm Technol. 2022 Aug;38(4):202-205. doi: 10.1177/87551225221094171. Epub 2022 May 10.
There is little clinical evidence comparing the safety and efficacy of prophylactic subcutaneous heparin given every 8 hours and every 12 hours. We performed a retrospective analysis incorporating these dosing intervals in an inpatient rehabilitation setting. : Heparin usage data was collected and patient charts were analyzed for both therapeutic failure and bleeding events. A 2-tailed Fisher's exact test was performed for both outcomes, with a -value of less than 0.05 being considered significant. Odds ratios were also calculated with -values less than 0.05 being considered significant. : A Cerner report was run to identify patients ordered prophylactic heparin in an inpatient rehabilitation setting from April 7, 2020, to October 27, 2021. One hundred patients receiving heparin every 8 hours and every 12 hours were randomly selected for chart review. These study groups were further stratified by Padua risk scores. : In both groups, 4 (4.0%) patients were identified as having a documented bleeding event and 2 (2.0%) patients from each group were identified as having a therapy failure. : For both endpoints, no significant differences in bleeding rates or therapy failure rates were detected in any of the population stratifications.
目前几乎没有临床证据可比较每8小时和每12小时预防性皮下注射肝素的安全性和有效性。我们在住院康复环境中对这些给药间隔进行了回顾性分析。收集肝素使用数据,并分析患者病历中的治疗失败和出血事件。对这两个结果均进行双侧Fisher精确检验,P值小于0.05被视为具有统计学意义。还计算了比值比,P值小于0.05被视为具有统计学意义。运行Cerner报告以识别2020年4月7日至2021年10月27日在住院康复环境中接受预防性肝素治疗的患者。随机选择100名每8小时和每12小时接受肝素治疗的患者进行病历审查。这些研究组根据帕多瓦风险评分进一步分层。在两组中,均有4名(4.0%)患者被记录有出血事件,每组有2名(2.0%)患者被确定有治疗失败。对于这两个终点,在任何人群分层中均未检测到出血率或治疗失败率的显著差异。